Results · Apr-Jun 2026 · filed 10 Aug 2026
AstraZeneca Pharma India Q1 FY27 results
Sales grew 30% to ₹683 crore from ₹526 crore in Apr-Jun 2025.
Operating profit fell 40% to ₹48.9 crore, an operating margin of 7.2% (down 8.2 points from a year ago).
Net profit fell 32% to ₹37.9 crore from ₹55.8 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +18%, net profit −15%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 682.8 | 526.3 | +30% |
| Operating profit (EBITDA) | 48.9 | 81.1 | −40% |
| Operating margin | 7.2% | 15.4% | −8.2 pts |
| Net profit | 37.9 | 55.8 | −32% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 15 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 12 Aug 2026Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 11 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 10 Aug 2026Shareholder Meeting / Postal Ballot-Outcome of AGM
- 10 Aug 2026Outcome Of The Board Meeting Held On Monday, August 10, 2026
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.